Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

• Daniel Aletaha, Tuhina Neogi, +32 authors Gillian Hawker
• Annals of the rheumatic diseases
• 2010

OBJECTIVE The 1987 American College of Rheumatology (ACR; formerly the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticised for their lack of… (More)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

• Josef S Smolen, Robert B M Landewé, +30 authors Désirée Mfm van der Heijde
• Annals of the rheumatic diseases
• 2014

In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic… (More)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

• Josef S Smolen, Robert B M Landewé, +32 authors Désirée Mfm van der Heijde
• Annals of the rheumatic diseases
• 2010

Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available. In this paper… (More)

Treating rheumatoid arthritis to target: recommendations of an international task force

• Josef S Smolen, Daniel Aletaha, +19 authors Désirée Mfm van der Heijde
• Annals of the rheumatic diseases
• 2010

BACKGROUND Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA). … (More)

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary…

• Stanley B. Cohen, Paul R Emery, +10 authors Mark C Totoritis
• Arthritis and rheumatism
• 2006

OBJECTIVE To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti-tumor… (More)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

• Justin A. Smolen, Robert B M Landewé, +10 authors Désirée Mfm van der Heijde
• Annals of the rheumatic diseases
• 2009

BACKGROUND Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. OBJECTIVE To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (MTX), in… (More)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

• Daniel E. Furst, E. C. Keystone, +17 authors Kevin L. Winthrop
• Annals of the rheumatic diseases
• 2006

These include: References http://ard.bmj.com/cgi/content/full/65/suppl_3/iii2#BIBL This article cites 240 articles, 58 of which can be accessed free at: Rapid responses… (More)

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

• Thomas J. Schnitzer, Gerd Rüdiger Burmester, +9 authors Christopher John Hawkey
• Lancet
• 2004

BACKGROUND Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the… (More)

Guidelines for musculoskeletal ultrasound in rheumatology.

• M. Backhaus, Gerd Rüdiger Burmester, +5 authors Bernhard Manger
• Annals of the rheumatic diseases
• 2001

1. Introduction Within the past decade, musculoskeletal ultra-sound (US) has become an established imaging technique for the diagnosis and follow up of patients with rheumatic diseases. 1–5 This has… (More)

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

• Michael E. Farkouh, Howard S. Kirshner, +15 authors James H. Chesebro
• Lancet
• 2004

BACKGROUND The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›